Naslov
Anti-HBc prevalence among Croatian blood donors over a 14-years period (2004-2017): Assessment of trends, risks and need for implementing routine testing

Autori
Miletić, Manuela ; Bingulac-Popović, Jasna ; Stojić Vidović, Miljana ; Hećimović, Ana ; Berendika, Mirka ; Babić, Ivana ; Đogić, Vesna ; Samardžija, Marko ; Barišić, Karmela ; Jukić, Irena ; Mihaljević, Ivanka

Izvornik
Transfusion clinique et biologique (1246-7820) 26 (2019); 257-262

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
blood donors ; anti-HBc seroprevalence ; OBI

Sažetak
Objectives. – The anti-HBc prevalence over a 14- year period (2004-2017), trends, infectivity, residual risk, and need for testing in blood donors (BD) of the Croatian Institute of Transfusion Medicine were assessed. Material and Methods. – Anti-HBc was tested in 19, 969 BD serum samples collected in 2004 (n=7, 561), 2013 (n=7, 318) and 2017 (n=5, 090). All serums were initially screened for HBsAg, anti-HCV, HIV Ag/Ab, and anti-TP. 2013 and 2017 samples were also tested by ID-NAT. Results. – Over a 14-years period, the anti-HBc prevalence significantly decreased among Croatian BD (5.90% in 2004, 2.56% in 2013, and 1.32% in 2017). Similarly, the prevalence of anti-HBc-only profiles decreased from 0.62% in 2004, 0.25% in 2013, and 0.21% in 2017. The 4-time decreasing trend was observed in all age groups of BD from 2017 but mostly among repeat donors (5.90% to 1.38%). First-time donors showed no significant difference in anti-HBc prevalence probably due to their younger age and HBV vaccine status. However, similar anti-HBs carriage rates (86.4%, 87.6%, and 82.1%) were reported in anti-HBc positive donors over the study period. HBsAg and HBV DNA were not detected. No OBI infection was found in the study despite an OBI frequency of 1:10, 900 donations previously reported in Croatia. A HBV decreasing residual risks of 68, 88, and 12 per million donations were estimated for years 2004, 2013, and 2017, respectively. Conclusion. – Anti-HBc testing is an additional measure of preventing HBV infection by transfusion. Implementation of anti-HBc testing will result in the deferral of 1.3% BD and should be supported by cost-benefit analyses.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA